Artificial Intelligence in Healthcare

The global AI in healthcare market is anticipated to reach $35,892.2 Million by 2030, registering a CAGR of 24.40%, during the forecast period 2021-2030. Owing to the COVID pandemic, the market grew with a significant growth rate in 2020. The global lockdown and social distancing norms highlighted the importance of remote monitoring, telemedicine, and technology integration in the primary healthcare system, which accelerated the market growth in 2020.

Market Segmentation

• Product Type (AI-Integrated Hardware and Software and Services)

• Technology (Machine Learning, Deep Learning, Natural Language Processing, Computer Vision, and Others)

• Application (Medical Imaging and Diagnosis, Data Management, Telemedicine, Remote Monitoring and Lifestyle Management, Robot-Assisted Surgery, Drug Discover and Clinical Trials, Virtual Assistance, and Others)

• End User (Patients, Healthcare Providers, Academic Institutes and Research Centers, Pharmaceutical Companies, Healthcare Insurance, and Others)

Regional Segmentation

• North America

• Europe

• Asia-Pacific

• Rest-of-the-World

Growth Drivers

• Growing Need for Patient-Centric Care

• Growing Applications of AI in Healthcare Informatics

• Shortage of Healthcare Workforce

• Increasing Complexities of Clinical Decision Making

• Progress in Healthcare IT

Market Restraints

• Lack of Clearly Defined Regulations

• Data Security and Privacy Concerns

• Barriers to Physician’s Adoption of AI

• Legal Implications of AI Systems

Market Opportunities

• Capitalizing on Unmet Clinical Demand

• Enabling Care At-Home: Remote Monitoring

• Leveraging Rapid Development in Deep Learning

• Unlocking the Combined Potential of AI and Robotics

Key Companies Profiled

Activ Surgical, Inc., Atomwise, Inc., Babylon Health, BenevolentAI, Butterfly Network, Inc., Freenome, General Electric Company, International Business Machines Corporation (IBM), Koninklijke Philips N.V., Nuance Communications, Inc., Nvidia Corporation, Olive, Siemens Healthineers AG, Viz.ai, Inc., and Zebra Medical Vision Ltd.

Request a Sample - https://bisresearch.com/requestsample?id=1068&type=download

Comments

Microbiome Therapeutics Market Growth, Segmentation, Opportunity and Forecast to 2032

Global microbiome therapeutics market is expected to grow further in the coming years due to the continuous increase in awareness and need for better and safer treatment alternatives and the dominance of gastrointestinal (GI) and infectious diseases segment can be attributed to the existing dominance of microbiome therapeutics available for a variety of indications ranging from diarrhea and gut dysbiosis to skin disorders, cancer indications among others. The global microbiome therapeutics market which accounted for $306.3 million in 2021 is expected to reach $3,204 million by 2032, reporting a CAGR of 24.95% during the forecast period 2022-2032. The existing microbiome therapeutics market is favored by multiple factors, including the rising geriatric populations coupled with the increasing adoption of inorganic growth strategies by key players in the market. Impact of COVID-19 There were numerous consequences due to the COVID-19 pandemic, especially...

PD-1/PDL-1 Inhibitor Market Growth Prospects, Emerging Trends and Forecast to 2032

PD-1/PDL-1 inhibitors are immune-therapeutic agents used in the treatment of various cancer indications, mostly in the advanced stages. PD-1/PDL-1 inhibitors are monoclonal antibodies majorly of IgG1 and IgG4 types to be administered to patients via injection The current market already has seven approved products in the U.S. and a large number of research activities are currently undergoing in this segment generating interest of commercial as well as academic research institutions. In the current period of precision medicine and providing targeted treatment, identification of target patient has become very important as well as complicated. With the emergence of diagnostic test identifying predictive biomarkers, the selection and administration of targeted treatment has become comparativlely conveninent and efficient. PD-1/PDL-1 inhibitors market are majorly indicated for the treatment of advanced cases of different cancer indications. The PD-1/PDL-1 inibitor treatment has ...

Ligase Market Opportunities, Strategies, Share, Segmentation, In-depth Analysis 2032

The global ligase market is progressing rapidly with a significant increase in the research and development activities pertaining to a wide range of ligase product for disease detection, accentuating their criticality in healthcare. Ligase enzyme has a critical role in the molecular diagnostics approach, as it ensures the safe and effective application of targeted therapeutics. Most of the players in the global ligase market offer products encompassing the ligation kits and enzymes. The global ligase market is projected to reach $651.4 million by 2032 from $371.2 million in 2021, at a CAGR of 5.29% during the forecast period 2022-2032. The growth in the global ligase market is expected to be driven by factors such as the increasing prevalence of infectious and genetic diseases on a global level, rising awareness of enzyme based diagnostic testing and significant number of funding for executing research and development. Impact Several techniques are employed in ...

Market Research Reports

Search This Blog